{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:22:51Z","timestamp":1787700171138,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106893","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:18:33Z","timestamp":1773173913000},"page":"106893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges of neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite-unstable localized colon cancer patients"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-7321","authenticated-orcid":false,"given":"M.","family":"Karoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-0004","authenticated-orcid":false,"given":"A.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.106893_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106893_bib2","doi-asserted-by":"crossref","first-page":"djv438","DOI":"10.1093\/jnci\/djv438","article-title":"Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study","volume":"108","author":"Tougeron","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106893_bib3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial","volume":"41","author":"Morton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106893_bib4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106893_bib5","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106893_bib6","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial","volume":"9","author":"Ta\u00efeb","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106893_bib7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106893_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106893_bib9","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106893_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106893_bib11","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.annonc.2024.05.019","article-title":"8MO: Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial","volume":"35","author":"Kasi","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106893_bib12","article-title":"NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer","volume":"42","author":"Shiu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106893_bib13","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106893_bib14","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO.2024.42.16_suppl.3505","article-title":"Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high\/mismatch repair-deficient colorectal cancer: results from a randomized, open-labeled, phase Ib study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106893_bib15","article-title":"IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI tumors: results of the colorectal cancer cohort","volume":"35","author":"de la Fouchardiere","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.106893_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2025.43.4_suppl.19","article-title":"Single-cycle neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: final analysis of the RESET-C study","volume":"43","author":"Qvortrup","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.106893_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2025.43.4_suppl.158","article-title":"Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO","volume":"43","author":"Ghelardi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106893_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMc2409154","article-title":"The duration of immunotherapy for mismatch repair-deficient cancers","volume":"392","author":"Rousseau","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106893_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","article-title":"Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22)","volume":"271","author":"Karoui","year":"2020","journal-title":"Ann Surg"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106893_bib20","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1200\/JCO.23.01889","article-title":"Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, phase III OPTICAL trial","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106893_bib21","article-title":"Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: the NeoCol trial","volume":"41","author":"Jensen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106893_bib22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2214\/AJR.15.15785","article-title":"Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis","volume":"207","author":"Nerad","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.esmoop.2026.106893_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2022.06.060","article-title":"Colon cancer CT staging according to mismatch repair status: comparison and suggestion of imaging features for high-risk colon cancer","volume":"174","author":"Hong","year":"2022","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106893_bib24","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.annonc.2025.05.126","article-title":"114P Radiologist concordance and pathology correlation in non metastatic colon cancer (NMCC) staging","volume":"36","author":"Randon","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106893_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68147-7","article-title":"Comparative evaluation of CT and MRI in the preoperative staging of colon cancer","volume":"14","author":"Bompou","year":"2024","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106893_bib26","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1007\/s00261-023-03904-2","article-title":"Radiologic T staging of colon cancer: renewed interest for clinical practice","volume":"48","author":"Chang","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106893_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13244-025-02038-x","article-title":"CT colonography: revisited after 30 years","volume":"16","author":"Cadi","year":"2025","journal-title":"Insights Imaging"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106893_bib28","article-title":"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer","volume":"43","author":"Sinicrope","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106893_bib29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106893_bib30","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:15:05Z","timestamp":1774487705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926008355"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106893","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite-unstable localized colon cancer patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106893"}}